ArticleStem cell research & therapy2026
Epidural cell therapy reduces neurological sequelae severity in canine distemper survivors.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCanine distemper has a high mortality rate in the acute phase, and survivors typically suffer irreversible, progressive neurological sequelae, due to demyelinating leukoencephalitis, under current treatment standards. Mesenchymal stromal cells (MSCs) are found in the adult organism and represent a promising alternative for treating central nervous system disorders by secreting trophic and immunomodulatory factors that reduce inflammation, protect neurons, and promote regeneration. The therapeutic action of MSCs is largely mediated by the secretion of trophic and immunomodulatory factors, including anti-inflammatory cytokines, anti-apoptotic proteins, and neurotrophins.
methodsThe objective of this study was to evaluate the effects of three epidurally administered doses of 1 million MSCs per kilogram of body weight at 30-day intervals in four dogs suffering neurological sequelae of canine distemper. Each animal was evaluated using an adapted application of the modified neurodisability scale (0-15 scale) and a quality-of-life questionnaire ranking behaviors (0-7 scale).
resultsStatistical analysis confirmed the significant effect of using multiple doses, and regression analysis revealed a significant influence of age and weight on treatment outcome. Additionally, a logistic regression predicting improvement over time was extrapolated from these results to help clinicians and owners make better-informed decisions regarding cellular therapy. Complete clinical remission of four of the five subcategories of the neurodisability score was achieved in all subjects, with one subject achieving full remission of myoclonus.
conclusionsThese results indicate that epidural MSC administration progressively reduced sequelae severity and improved patient quality of life of the four canine distemper survivors that participated in this study, supporting the translation of cellular therapies into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.